| velsecorat (AZD7594) / AstraZeneca |
NCT01636024: To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 |
|
|
| Completed | 1 | 73 | Europe | AZD7594, Placebo to match | AstraZeneca | Safety, Pharmacokinetics, Pharmacodynamics of AZD7594 | 06/13 | 06/13 | | |
NCT02645253: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men |
|
|
| Completed | 1 | 27 | US | AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg), AZD7594 placebo inhalation powder, AZD7594 placebo pressurized inhalation suspension | AstraZeneca | Asthma, Chronic Obstructive Pulmonary Disease COPD | 04/16 | 04/16 | | |
NCT02648438: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects |
|
|
| Completed | 1 | 30 | US | AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI | AstraZeneca | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 06/16 | 06/16 | | |
NCT02928354: A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers |
|
|
| Completed | 1 | 12 | Europe | Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594 | AstraZeneca | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 03/17 | 03/17 | | |
NCT02967159: A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants |
|
|
| Completed | 1 | 14 | Europe | Abediterol, Treatment A, AZD7594, Treatment B, AZD7594/abediterol, Treatment C, AZD7594 and abediterol, Treatment D | AstraZeneca, Parexel | Chronic Obstructive Pulmonary Disease (COPD), Asthma | 04/17 | 04/17 | | |
NCT04002427: Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594 |
|
|
| Completed | 1 | 6 | Europe | Intravenous Infusion, Inhaled dose | AstraZeneca, Quotient Sciences | Asthma | 07/19 | 07/19 | | |
NCT04072562: A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. |
|
|
| Completed | 1 | 24 | Europe | AZD7594 | AstraZeneca, Parexel | Asthma | 11/19 | 11/19 | | |
AMBER, NCT03976869 / 2019-001259-37: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma |
|
|
| Completed | 1 | 36 | US | AZD7594 | AstraZeneca, Parexel | Asthma | 07/20 | 07/20 | | |
